Pharmacotherapy for hyperammonemia

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 12, 2014, Pages 1685-1695

  Hadjihambi, Anna ^a   Khetan, Varun ^a   Jalan, Rajiv ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Acute liver failure; Chronic liver failure; Hepatic encephalopathy; Hyperammonemia; Ornithine phenylacetate

Indexed keywords

ALBUMIN; AMMONIA; ANTIBIOTIC AGENT; CARNITINE; GLUTAMINASE; GLYCEROL PHENYLBUTYRATE; LACTULOSE; ORNITHINE ASPARTATE; ORNITHINE PHENYLACETATE; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN;

ALBUMIN DIALYSIS; AMMONIA FORMATION; BRAIN; DRUG EFFICACY; DRUG THERAPY; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; INTESTINE; KIDNEY; LIVER; MUSCLE; NONHUMAN; NUTRITION; PROTEIN RESTRICTION; REVIEW; UREA CYCLE;

ACUTE LIVER FAILURE; CHRONIC LIVER FAILURE; HEPATIC ENCEPHALOPATHY; HYPERAMMONEMIA; ORNITHINE PHENYLACETATE;

AMMONIA; ANIMALS; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERAMMONEMIA; LACTULOSE; RIFAMYCINS; SORPTION DETOXIFICATION;

EID: 84904681449     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.931372     Document Type: Review

References (94)

1. Ciecko-Michalska I, Malgorzata S, Agnieszka S, et al. Pathogenesis of HE. Gastroenterol Res Pract 2012;2012:7
2. Ferenci P, Lockwood A, Mullen K, et al. HE-definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2004;35:716-21
3. Prakash R, Mullen KD. Mechanisms, diagnosis and management of HE. Nat Rev Gastroenterol Hepatol 2010;7(9):515-25
4. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol 2002;67:259-79
5. Jalan R, Olde Damink SW, Hayes PC, et al. Pathogenesis of intracranial hypertension in acute liver failure: Inflammation, ammonia and cerebral blood flow. J Hepatol 2004;41:613-20
6. Bosoi CR, Rose CF. Oxidative stress: A systemic factor implicated in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2013;28(2):175-8
7. Butterworth RF. The astrocytic ("peripheral-Type") benzodiazepine receptor: Role in the pathogenesis of portal-systemic encephalopathy. Neurochem Int 2010;36(4-5):411-16
8. Li T, Li X, Zhou W, et al. Dynamic susceptibility contrast-enhanced first-pass perfusion MR imaging in patients with subclinical hepatic encephalopathy. J Neuroradiol 2012;39(5):290-4
9. Butterworth RF, Gigure JF, Michaud J, et al. Ammonia: Key factor in the pathogenesis of HE. Neurochem Pathol 1987;6(1,2):1-12
10. Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther 2012;92(3):321-31
11. Burton BK. Urea cycle disorders. Clin Liver Dis 2000;4(4):815-30
12. Wakim-Fleming J. HE: Suspect it early in patients with cirrhosis. Cleve Clin J Med 2000;78(9):597-605
13. Bosoi CR, Rose CF. Brain edema in acute liver failure and chronic liver disease: Similarities and differences. Neurochem Int 2013;62(4):446-57
14. Grubinko VV, Iavonenko OF. Multiple molecular forms of glutamine synthetase in carp muscles. Ukr Biokhim Zh 2001;63(2):72-7
15. Klaus U. Comparative animal biochemistry. Springer-Verlag; Berlin Heidelberg: 1994
16. Matthews GD, Gur N, Koopman WJH, et al. Weak mitochondrial targeting sequence determines tissue-specific subcellular localization of glutamine synthetase in liver and brain cells. J Cell Sci 2010;123:351-9
17. Olde Damink SW, Jalan R, Dejong CH. Interorgan ammonia trafficking in liver disease. Metab Brain Dis 2009;24:169-81
18. Haussinger D, Kircheis G, Fischer R, et al. HE in chronic liver disease: A clinical manifestation of astrocyte swelling and low-grade cerebral edema?. J Hepatol 2000;32(6):1035-8
19. Olde Damink OS, Deutz NE, Dejong CH, et al. Interorgan ammonia metabolism in liver failure. Neurochem Int 2002;41(2-3):177-88
20. Gaasbeek Janzen JW, Gebhardt R, Ten Voorde GH, et al. Heterogeneous distribution of glutamine synthetase during rat liver development. J Histochem Cytochem 1987;35:49-54
21. Haussinger D. Regulation of hepatic ammonia metabolism: The intercellular glutamine cycle. Adv Enzyme Regul 1986;25:159-80
22. Haussinger D. Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver. Eur J Biochem 1983;133:269-75
23. Welbourne TC. Hepatic glutaminase flux regulation of glutamine homeostasis. Studies in vivo. Biol Chem 1986;367:301-5
24. Jalan R, Wright G, Davies NA, et al L-Ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 2007;69(5):1064-9
25. Kaiser S, Gerok W, Haussinger D. Ammonia and glutamine metabolism in human liver slices: New aspects on the pathogenesis of hyperammonaemia in chronic liver disease. Eur J Clin Invest 1988;18:535-42
26. Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 1995;15:133-59
27. Tannen RL. Ammonia metabolism. Am J Physiol 1978;235:F265-77
28. McDermott WV, Adams RD, Riddel AG. Ammonia metabolism in man. Ann Surg 1954;140:539-56
29. Owen EE, Robinson RR. Amino acid extraction and ammonia metabolism by the human kidney during prolonged administration of ammonium chloride. J Clin Invest 1963;42:263-76
30. Vinay P, Allignet E, Pichette C, et al. Changes in renal metabolite profile and ammoniagenesis during acute and chronic metabolic acidosis in dog and rat. Kidney Int 1980;17:312-25
31. Vinay P, Lemieux G, Gougoux A, et al. Regulation of glutamine metabolism in dog kidney in vivo. Kidney Int 1986;29:68-79
32. Junco E, Perez R, Jofre R, et al. Acute and chronic metabolic acidosis in the pig: Renal metabolism and ammoniagenesis. In: Endou H, Schoolwerth AC, Baverel G, Tizianello A, editors. molecular aspects of ammoniagenesis. Karger; Basel: Contrib Nephrol 1991. p. 92:18-30
33. Welbourne TC, Childress D, Givens G. Renal regulation of interorgan glutamine flow in metabolic acidosis. Am J Physiol 1986;251:R858-66
34. Berry JN, Flanagan JF, Owen EE, et al. The kidney as a source of blood ammonia in resting and hyperventilated cirrhotics. Clin Res 1959;7:154-5
35. Owen EE, Tyor MP, Flanagan JF, et al. The kidney as a source of blood ammonia in patients with liver disease: The effect of acetazolamide. J Clin Invest 1960;39:288-94
36. Owen EE, Johnson JH, Tyor MP. The effect of induced hyperammonemia on renal ammonia metabolism. J Clin Invest 1961;40:215-21
37. Tyor MP, Owen EE, Berry JN, et al. The relative role of extremity, liver and kidney as ammonia receivers and donors in patients with liver disease. Gastroenterology 1960;39:420-4
38. Deutz NE, Dejong CH, et al. Interorgan ammonia and glutamine exchange during liver failure. In: Record CO, Mardini HA, editors. Advances in HE and metabolism in liver disease. University of Newcastle upon Tyne; Newcastle upon Tyne: 1996. p. 87-99
39. Welters CF, Deutz NE, Dejong CH, et al. Enhanced renal vein ammonia efflux after a protein meal in the pig. J Hepatol 1999;31:489-96
40. Olde Damink SW, Jalan R, Redhead DN, et al. Enhanced renal ammonia production is a major cause of hyperammonemia after a simulated bleed in patients with cirrhosis of the liver. Eur J Gastroent Hepatol 1999;11:A83
41. Lockwood AH, McDonald JM, Reiman RE, et al. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 1979;63:449-60
42. Dejong CH, Deutz NE, Soeters PB. Intestinal glutamine and ammonia metabolism during chronic hyperammonaemia induced by liver insufficiency. Gut 1993;34:1112-19
43. Dejong CH, Kampman MT, Deutz NE, et al. Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia. Gastroenterology 1992;102:936-48
44. Dejong CH, Deutz NE, Soeters PB. Cerebral cortex ammonia and glutamine metabolism in two rat models of chronic liver insufficiency-induced hyperammonemia: Influence of pair-feeding. J Neurochem 1993;60:1047-57
45. Wolpert E, Phillips SF, Summerskill WH. Ammonia production in the human colon. Effects of cleansing. N Engl J Med 1970;283:159-64
46. Windmueller HG. Glutamine utilization by the small intestine. Adv Enzyme Regul 1982;53:210-37
47. Windmueller HG, Spaeth AE. Identification of ketone bodies and glutamine as the major respiratory fuels in vivo for post-Absorptive rat small intestine. J Biol Chem 1978;253:69-76
48. Weber Jr. FL, Veach GL. The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology 1979;77:235-40
49. Lorette N, Baigent S, Jalan R. Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamics, and by organ function: A quantitative modelling study. Liver Int 2013; Epub ahead of print 50. Jalan R, Hayes PC. HE and ascites. Lancet 1997;350:1309-15
50. Nencki M, Pawlow JP, Zaleski J. Ueber den ammoniakgehalt des blutes und der organe und die harnstoffbildung bei den saugethieren. Arch Exp Pathol Pharm 1896;37:26-51
51. Lund P. A radiochemical assay for glutamine synthetase, and activity of the enzyme in rat tissues. Biochem J 1970;118:35-9
52. Nelson D, Rumsey WL, Erecinska M. Glutamine catabolism by heart muscle. Biochem J 1992;282:559-64
53. Warter JM, Marescaux C, Brandt C, et al. Sodium valproate associated with phenobarbital: Effects on ammonia metabolism in humans. Epilepsia 1983;24:628-33
54. Eriksson LS, Broberg S, Bjorkman O, et al. Ammonia metabolism during exercise in man. Clin Physiol 1985;5:325-36
55. Webster LT, Gabuzda GJ. Ammonium uptake by the extremities and brain in hepatic coma. J Clin Invest 1958;37:414-24
56. Ganda OP, Ruderman NB. Muscle nitrogen metabolism in chronic hepatic insufficiency. Metabolism 1976;25:427-35
57. Clemmesen JO, Kondrup J, Ott P. Splanchnic and leg exchange of amino acids and ammonia in acute liver failure. Gastroenterology 2000;118:1131-9
58. Ruderman NB, Lund P. Amino acid metabolism in skeletal muscle. Regulation of glutamine and alanine release in the perfused rat hindquarter. Israel J Med Sci 1972;8:295-302
59. Plauth M, Merli M, Kondrup J. Management of HE. N Eng J Med 1997;337:1921-2
60. Kondrup J, Mueller MJ. Energy and protein requirements of patients with chronic liver disease. J Hepatol 1997;27:239-47
61. Stein TP. Nutrition and protein turnover: A review. JPEN 1982;35:1202-10
62. Cunningham-Rundles S. Effect of nutritional status on immunological function. Am J Clin Nutr 1982;35:1202-10
63. Walker WA. Cellular and immune changes in the gastrointestinal tract in malnutrition. In: Winick M, editor. Nutrition and gas-Troenterology. Wiley; New York: 1980. p. 197-218
64. Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis?. Hepatology 1996;23:1041-6
65. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic HE: Results of a randomized study. J Hepatol 2004;41(1):38-43
66. Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of HE in cirrhosis: An open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012;107:1043-50
67. Haemmerli UP, Bircher J. Influence of lactulose treatment in non-ionic diffusion of ammonia in the dog colon. Gastroenterology 1969;56:1163
68. Gluud LL, Dam G Borre M, et al. Lactulose, rifaximin or branched chain amino acids for HE: What is the evidence?. Metab Brain Dis 2013;28:221-5
69. Als-Nielsen B, Gluud LL, Gluud C. Treatment of hepatic encephalopathy: Authors' reply. BMJ 2004;329:112.2
70. Ferenci P. HE in Adults: Treatment. UptoDate. Available from: Http:/www. uptodate.com/contents/hepaticencephalopathy-in-Adults-Treatment [Accessed on 1 March 2014]
71. Bajaj JS, Sanyal AJ, Bell D, et al. Predictors of the recurrence of hepatic encephalopathy in lactulose-Treated patients. Aliment Pharmacol Ther 2010;31(9):1012-17
72. Wu D, Wu SM, Lu J, et al. Rifaximin versus nonabsorbable disaccharides for the treatment of HE: A meta-Analysis. Gastroenterol Res Pract 2013;2013:236963
73. Mas A, Rodes J, Sunyer L, et al. Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38(1):51-8
74. Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt HE. Am J Gastroenterol 2013;108(9):1458-63
75. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in HE. N Engl J Med 2010;362:1071-81
76. Bai M, Yang Z, Qi X, et al. l-ornithinel-Aspartate for HE in patients with cirrhosis: A meta-Analysis of randomized controlled trials. J Gastroenterol Hepatol 2013;28:783-92
77. Zullo A, Lorenzo R, Cesare H. Rifaximin therapy and clostridium difficile infection: A note of caution. J Clin Gastroenterol 2013;47(8):737
78. Acharya SK, Bhatia V, Sreenivas V, et al. Efficacy of L-ornithine L-Aspartate in acute liver failure: A double-blind, randomized, placebo-controlled study. Gastroenterology 2009;136:2159-68
79. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-Laspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study. Hepatology 1997;25(6):1351-60
80. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-Aspartate therapy of chronic hepatic encephalopathy: Results of a placebo-controlled double-blind study. J Hepatol 1998;28(5):856-64
81. Malaguarnera M, Bella R, Vacante M, et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal HE. Scand J Gastroenterol 2011;46:750-9
82. Dam G, Keiding S, Munk OL, et al. Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. Am J Physiol Gastrointest Liver Physiol 2011;301:G269-77
83. Gluud LL, Dam G, Borre M, et al. Lactulose, rifaximin or branched chain amino acids for HE: What is the evidence?. Metab Brain Dis 2013;28:221-5
84. Cordoba J, Blei AT, Mujais S. Determinants of ammonia clearance by hemodialysis. Artif Organs 1996;20:800-3
85. Hassanein TI, Tofteng F, Brown Jr, RS et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007;46(6):1853-62
86. Karvellas CJ, Gibney N, Kutsogiannis D, et al. Bench-To-bedside review: Current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care 2007;11:215
87. Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory HE: A multicenter survey on safety and efficacy. Hepatology 2013;57:2448-57
88. Simon-Talero M, Garcia-Martinez R, Torrens M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic HE: A randomized double-blind study. J Hepatol 2013;59:1184-92
89. Davies NA, Wright G, Ytrebø LM, et al. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology 2009;50(1):155-64
90. Hassanein TI, Tofteng F, Brown Jr, RS et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007;46(6):1853-62
91. Ventura-Cots M, Arranz JA, Simon-Talero M, et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: An open-label, dose-escalating, single-cohort. J Clin Gastroenterol 2013;47(10):881-7
92. Jover-Cobos M, Noiret L, Lee K, et al. Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats. J Hepatol 2014;60(3):545-53
93. Ytrebø LM, Kristiansen RG, Maehre H, et al. Show all. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. J Hepatol 2009;50(1):165-74
94. Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in HE. Hepatology 2013;56:248A.